medicaldialogues.in
Cure8 news brief
Why This Matters
This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial results showing improved clinical remission and endoscopic healing versus placebo.
Who Should Pay Attention
Adults with moderately to severely active Crohn's disease, patients who have failed or lost response to other therapies, clinicians treating IBD, and researchers following IL‑23–targeting treatments.
Study Snapshot
Story typeResearch news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Omvoh (mirikizumab) is an IL-23 p19–targeting biologic already approved for ulcerative colitis; this FDA decision adds Crohn's disease as an indication for adults. The VIVID-1 randomized trial led to the approval; an open‑label extension (VIVID-2) is ongoing to assess longer-term efficacy and safety.
The article summarizes company and expert statements and notes common biologic safety warnings in the US label. If you are considering a new therapy for Crohn's disease, discuss with your gastroenterology team whether mirikizumab is appropriate for you—this article reports approval and trial results but does not replace individualized medical advice.
Keep In Mind
The article summarizes company and investigator comments and trial outcomes from the VIVID studies; it is not a detailed clinical guideline. Safety warnings are noted in the label. Ongoing open‑label studies will provide longer‑term data. Talk with your clinician about how trial populations and outcomes relate to your situation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedicaldialogues.in
Indexed viaBing News
Source typeResearch news
PublishedJan 15, 2025, 10:00 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...
Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.